The Health Impact of, and access to, New Drugs in Korea
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
We perform an econometric assessment of the role that pharmaceutical innovation— the introduction and use of new drugs—has played in improving the health of Koreans, by investigating whether diseases for which more new drugs were launched had larger subsequent increases in longevity and smaller subsequent increases in hospitalization. Drugs launched during 1993-2012 are estimated to have increased mean age at death from all diseases by 1.71 years between 1995 and 2015 and 1.09 years between 2005 and 2015. We also estimate that new drugs increased the five-year relative survival rate from all cancers combined by 23.2 percentage points—78.5% of the total increase—between 1993-1995 and 2011-2015, and that new drugs launched during 2008-2010 reduced the number of hospital days in 2017 by 13.0 million. If the drugs launched during 2003-2012 had had no effect on other medical expenditure in 2015, the cost per life-year gained would not have exceeded 6332 USD. Therefore, even if we ignore the effect of new drugs on hospital utilization, the drugs launched during 2003-2012 were very cost–effective, overall. When reduced hospital utilization is accounted for, the evidence indicates that, in the long run, pharmaceutical innovation was cost-saving as well as life-year saving.
Abstract
We perform an econometric assessment of the role that pharmaceutical innovation— the introduction and use of new drugs—has played in improving the health of Koreans, by investigating whether diseases for which more new drugs were launched had larger subsequent increases in longevity and smaller subsequent increases in hospitalization. Drugs launched during 1993-2012 are estimated to have increased mean age at death from all diseases by 1.71 years between 1995 and 2015 and 1.09 years between 2005 and 2015. We also estimate that new drugs increased the five-year relative survival rate from all cancers combined by 23.2 percentage points—78.5% of the total increase—between 1993-1995 and 2011-2015, and that new drugs launched during 2008-2010 reduced the number of hospital days in 2017 by 13.0 million. If the drugs launched during 2003-2012 had had no effect on other medical expenditure in 2015, the cost per life-year gained would not have exceeded 6332 USD. Therefore, even if we ignore the effect of new drugs on hospital utilization, the drugs launched during 2003-2012 were very cost–effective, overall. When reduced hospital utilization is accounted for, the evidence indicates that, in the long run, pharmaceutical innovation was cost-saving as well as life-year saving.
참고문헌 (33)
- Aghion, P., "Handbook of Economic Growth. vol. 1, part A", pp.67~110 (2005), Elsevier
- Bertram, M. Y., "Cost-Effectiveness Thresholds: Pros and Cons", Bulletin World Health Organization, 94(12), pp.925~930 (2016)
- Measuring the Growth from Better and Better Goods, "Bils, M.", NBER, ~, pp.NBER Working Paper, no. 10606 (2004)
- Bresnahan, T. F., "The Economics of New Goods" (1996), University of Chicago Press
- "Thériaque database" (2019)[URL]
- Dorsey, E. R., "Financial Anatomy of Biomedical Research, 2003-2008", Journal of the American Medical Association, 303(2), pp.137~143 (2010)
- Grossman, G. M., "Innovation and Growth in the Global Economy" (1991), MIT Press
- Hausman, J., "Mismeasured Variables in Econometric Analysis: Problems from the Right and Problems from the Left", Journal of Economic Perspectives, 15(4), pp.57~67 (2001)
- "The Pharmaceutical Industry and Global Health: Facts and Figures 2017" (2017)[URL]
- Jones, C. I., "Introduction to Economic Growth" (1998), W.W. Norton
- Jones, C. I., "Sources of U.S. Economic Growth in a World of Ideas", American Economic Review, 92(1), pp.220~239 (2002)
- Jovanovic, B., "Investment in Vintage Capital", Journal of Economic Theory, 147(2), pp.551~569 (2012)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2015", Cancer Research and Treatment, 50(2), pp.303~316 (2018), 대한암학회
- Koç, C., "The Productivity of Health Care and Health Production Functions", Health Economics, 13(8), pp.739~747 (2004)
- Kolata, G., "Surgery for Blocked Arteries Is Often Unwarranted, Researchers Find", New York Times, vol. 169, no. 58,514, Section A, 19~ (2019)
- Lichtenberg, F. R., "Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence from Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003", Health Economics, 18(5), pp.519~534 (2009)
- Lichtenberg, F. R., "Has Medical Innovation Reduced Cancer Mortality?", CESifo Economic Studies, 60(1), pp.135~177 (2014)
- Lichtenberg, F. R., "The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in France, 2000-2009", Economics and Human Biology, 13, pp.107~127 (2014)
- Lichtenberg, F. R., "Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009", Health Policy and Technology, 3(1), pp.36~58 (2014)
- Lichtenberg, F. R., "The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010", Journal of Human Capital, 8(4), pp.432~480 (2014)
- Frank R. Lichtenberg, "The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis", Forum for Health Economics and Policy, 21(2) (2018), Walter de Gruyter GmbH[DOI]
- "Long-Term Trial Results Show No Mortality Benefit from Annual Prostate Cancer Screening" (2012)[URL]
- "Enhancing Drug Discovery and Development" (2019)[URL]
- "The Guidelines Manual: Assessing cost effectiveness" (2019)[URL]
- Nordhaus, W. D., "Irving Fisher and The Contribution of Improved Longevity to Living Standards", American Journal of Economics and Sociology, 64(1), pp.367~392 (2005)
- "OECD Health Statistics 2019 Definitions, Sources and Methods Hospital discharges by diagnostic categories" (2019)[URL]
- "International shortlist for hospital morbidity tabulation" (2019)[URL]
- "OECD Health Statistics database" (2019)[URL]
- Sampat, B., "What are the Respective Roles of the Public and Private Sectors in Pharmaceutical Innovation?", Health Affairs, 30(2), pp.332~339 (2011)
- "2009 Life Tables for Korea" (2010)[URL]
- "Budget Impact Analysis" (2019)[URL]
- "Cause of Death Query online database" (2019)[URL]
- Yang, S., "Understanding the rapid increase in life expectancy in South Korea", American Journal of Public Health, 100(5), pp.896~903 (2010)